Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.57 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.57 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5527107 | 0.82 | GAA (0.55) | MCL1LMNAHPGDGAAKMT2A | |
| SCHEMBL11305585 | 0.81 | MEN1 (0.63) | HPGDGAAKMT2AMEN1CYP2C19 | |
| SCHEMBL669951 | 0.80 | GAA (0.53) | MCL1LMNAHPGDGAAKMT2A | |
| SCHEMBL17763698 | 0.79 | MCL1 (0.61) | MCL1LMNAPLIN1PLIN5ABHD5 | |
| SCHEMBL17814271 | 0.79 | MCL1 (0.61) | MCL1LMNAPLIN1PLIN5ABHD5 | |
| SCHEMBL17763697 | 0.79 | MCL1 (0.61) | MCL1LMNAPLIN1PLIN5ABHD5 | |
| SCHEMBL7544299 | 0.78 | MCL1 (0.60) | MCL1LMNAPLIN1PLIN5ABHD5 | |
| SCHEMBL654148 | 0.77 | MCL1 (1.00) | MCL1LMNAHPGDGAAKMT2A | |
| SCHEMBL23942226 | 0.77 | LMNA (0.75) | MCL1LMNAPLIN1PLIN5ABHD5 | |
| SCHEMBL3056874 | 0.76 | KMT2A (0.71) | LMNAHPGDGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096499-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-06 | — | — | US | disclosed |
| US-8648102-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120214850-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | PRIEBE WALDEMAR (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2487156-A1 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1701941-B1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | UNIV TEXAS (US) | 2012-05-30 | — | — | EP | disclosed |
| US-8119827-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1701941-A4 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | UNIV TEXAS (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1701941-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | Board of Regents, The University of Texas System (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20050277680-A1 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-12-15 | — | — | US | disclosed |
| WO-2005058829-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | MCL1 9/4885LMNA 1969/4885PLIN1 1688/4885 |
| US-20120214850-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | MCL1 9/4885LMNA 1969/4885PLIN1 1688/4885 |
| US-20050277680-A1 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | MYC, MYCBP, ERBB2 | MCL1 37/4885LMNA 3442/4885PLIN1 1991/4885 |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | MCL1 9/4885LMNA 1969/4885PLIN1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.